沙罗格列扎治疗原发性胆汁性胆管炎的概念验证研究
这项双盲II期概念验证试验将37例UDCA抵抗或不耐受的原发性胆汁性胆管炎患者随机分为沙罗格列扎4mg组(n=13)、2mg组(n=14)和安慰剂组(n=10),每日给药16周。主要终点为第16周碱性磷酸酶(ALP)水平下降,两个沙罗格列扎组均较安慰剂组显著降低,且第4周即快速下降并维持。沙罗格列扎2mg和4mg每日给药耐受性良好,但因4mg组肝酶升高发生率较高,后续研究采用2mg和1mg剂量。
要点
- 沙罗格列扎4mg和2mg组第16周ALP较基线显著下降,安慰剂组变化较小。
- ALP在第4周即快速下降并维持至研究结束。
- 4mg组肝酶升高导致3例停药,后续研究改用2mg和1mg剂量。
核心结论
- 沙罗格列扎2mg和4mg每日给药耐受性良好,并导致ALP快速且持续改善。
- 因4mg剂量肝酶升高发生率较高,后续研究采用每日2mg和1mg剂量。
研究设计与样本
- 双盲、II期概念验证试验,37例UDCA抵抗或不耐受的原发性胆汁性胆管炎患者随机分为沙罗格列扎4mg(n=13)、2mg(n=14)或安慰剂(n=10)每日给药16周。
- 主要疗效终点为第16周ALP水平下降。
主要发现
- 第16周ALP较基线最小二乘均值变化:沙罗格列扎4mg组-163.3 U/L(SE=25.1,p<0.001),2mg组-155.8 U/L(SE=24.4,p<0.001),安慰剂组-21.1 U/L(SE=28.9)。
- 沙罗格列扎治疗第4周ALP快速下降并持续至研究结束。
- 至少1例治疗中出现的不良事件发生率:4mg组11例(84.6%),2mg组12例(85.7%),安慰剂组8例(80%)。
- 因氨基转移酶升高停药:4mg组3例,2mg组1例,停药后氨基转移酶迅速恢复至基线值。
- ALP平均百分比下降:沙罗格列扎4mg组49%,2mg组51%,安慰剂组3%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIM: Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with dual agonistic properties (α/γ). Due to a strong mechanistic rationale, we aimed to test the safety and efficacy of saroglitazar in patients with primary biliary cholangitis (PBC) who were either ursodeoxycholic acid (UDCA) resistant or intolerant. METHODS: In this double-blind, phase II proof-of-concept trial, 37 patients with PBC were randomized to saroglitazar 4 mg (n = 13), saroglitazar 2 mg (n = 14), or placebo (n = 10) daily for 16 weeks. The primary efficacy endpoint was the reduction in alkaline phosphatase (ALP) level at Week 16. RESULTS: A significant reduction of mean ALP levels was observed at Week 16 relative to baseline in both the saroglitazar 4 mg (least-squares [LS] mean =-163.3 U/L, SE = 25.1, p <0.001) and 2 mg (LS mean =-155.8 U/L, SE = 24.4, p <0.001) groups, compared with placebo (LS mean =-21.1 U/L, SE = 28.9). Treatment with saroglitazar resulted in a rapid reduction of ALP concentration at Week 4 that was sustained through the study duration. At least 1 treatment-emergent adverse event occurred in 11 (84.6%) patients in the saroglitazar 4 mg group, in 12 (85.7%) patients in the 2 mg group and in 8 (80%) patients in the placebo group. Study drug was discontinued in 4 patients (3 patients in the 4 mg group and 1 patient in the 2 mg group) due to aminotransferase increases that promptly returned to baseline values after drug discontinuation. CONCLUSIONS: Saroglitazar at 2 mg and 4 mg daily was tolerated and resulted in rapid and sustained improvements in ALP. Further studies are underway at a daily dose of 2 mg and 1 mg due to the higher incidence of elevated liver enzymes observed with the 4 mg dose. CLINICALTRIALS. GOV IDENTIFIER: NCT03112681 LAY SUMMARY: Saroglitazar resulted in a rapid and sustained improvement in alkaline phosphatase levels in patients with primary biliary cholangitis. The mean percentage reductions in alkaline phosphatase levels were 49% and 51% in the saroglitazar 4 mg and 2 mg groups compared to 3% in the placebo group.
引用
- Vuppalanchi R, Caldwell SH, Pyrsopoulos N, et al. Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis. J Hepatol. 2021. PMID: 34487750. doi:10.1016/j.jhep.2021.08.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。